Business Context and Reporting Period
This Form 8-K is a current report filed by Imprimis Pharmaceuticals, Inc. (not Harrow, Inc.) on March 12, 2018. The registrant is incorporated in Delaware and maintains its principal executive offices in San Diego, California. The filing serves as a Regulation FD disclosure regarding investor communications.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report is a procedural filing to disclose the existence of a presentation and fact sheet rather than a financial statement.
Material Changes
No material financial changes or operational updates are detailed within the body of this filing. The document solely references the attachment of a presentation and fact sheet used by management at investor conferences.
Guidance, Outlook, and Risks
- Regulation FD Disclosure: The company attached a March 2018 presentation (Exhibit 99.1) and fact sheet (Exhibit 99.2) to satisfy Regulation FD requirements.
- Legal Disclaimers: The information in the exhibits is not deemed "filed" under Section 18 of the Exchange Act and is not incorporated by reference into other filings unless specifically stated. The company assumes no obligation to update this information in the future.
- Outlook: No specific financial guidance or forward-looking statements are included in the text of this 8-K.
Key Facts for Investor Verification
- Verify the content of Exhibit 99.1 (Presentation) and Exhibit 99.2 (Fact Sheet) for actual business updates, as the 8-K text only references them.
- Confirm the company name is Imprimis Pharmaceuticals, Inc., noting the discrepancy with the metadata label "HARROW, INC."
- Note that the attached materials are not legally "filed" for liability purposes under Section 18 of the Exchange Act.